Optimal anti-amyloid-beta therapy for Alzheimer's disease via a personalized mathematical model.

ABSTRACT: With the recent approval by the FDA of the first disease-modifying drug for Alzheimer's Disease (AD), personalized medicine will be increasingly important for appropriate management and counseling of patients with AD and those at risk. The growing availability of clinical biomarker data and data-driven computational modeling techniques provide an opportunity for new approaches to individualized AD therapeutic planning. In this paper, we develop a new mathematical model, based on AD cognitive, cerebrospinal fluid (CSF) and MRI biomarkers, to provide a personalized optimal treatment plan for individuals. This model is parameterized by biomarker data from the AD Neuroimaging Initiative (ADNI) cohort, a large multi-institutional database monitoring the natural history of subjects with AD and m

SUBMITTER: Hao W 

PROVIDER: S-EPMC9477429 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature